Sign inJoin waitlistJoin the waitlist

Karam Khaddour

Instructor in Medicine · Harvard Medical School

Credentials: · · · · · · ·

History

Dana-Farber Cancer Institute
2023–Present
Harvard Medical School
Present

Research

Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review)
Review · International Journal of Oncology · 2022 · Co-first of 10 authors · 95 citations
The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions
Review · Pharmaceuticals · 2020 · First of 3 authors · Corresponding · 61 citations
Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies
Review · Cancers · 2021 · First of 8 authors · Corresponding · 52 citations

GA
George Ansstas
18 papers
Ann Silk
15 papers
Justine Cohen
7 papers
Manisha Thakuria
7 papers
Emily Ruiz
6 papers
Danielle Margalit
5 papers
Jiayi Huang
5 papers
MA
Michael Ansstas
5 papers
Omar Butt
5 papers · 4 as a fellow
AZ
Alice Zhou
4 papers · 1 as a resident
Eleni Rettig
4 papers
EB
Elizabeth Buchbinder
4 papers

Clinical trials

TIL Therapy in cSCC and MCC
Principal investigator · Recruiting · Phase 2
Karam Khaddour, MD, MS
2026–2029
A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
Principal investigator · Recruiting · Early phase 1
Dana-Farber Cancer Institute
2024–2026
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Site PI · Recruiting · Phase 2, Phase 3
TuHURA Biosciences, Inc.
2025–2032